Insight

ADVI Instant

Insights,

Feb 14 2023 | Jared Samuels - Manager

ADVI Instant: HHS Releases CMMI Drug Pricing Models Testing Report

ADVI Instant

Insights,

Feb 02 2023 | Brenna Raines, MHA - Senior Director

ADVI Instant: CMS Releases 2024 Medicare Advantage and Part D Advance Notice

Insights,

Jan 27 2023 | Allison Schneider, MHA - Senior Manager

ADVI Analysis: MACPAC Meeting January 2023

Insights,

Jan 13 2023 | Lindsay Bealor Greenleaf, JD, MBA - Head of Federal and State Policy

ADVI Analysis: MedPAC Meeting January 2023

Insights,

Dec 29 2022 | Lindsay Bealor Greenleaf, JD, MBA - Head of Federal and State Policy

House and Senate Pass the Consolidated Appropriations Act of 2023

Insights,

Nov 30 2022 | Caitlin Sheetz, MPH - Head of SAVEs

ADVI SAVEs Analysis: Trends in New COVID-19 Treatment Add-on Payments (NCTAP) in Medicare Fee-For-Service

Insights,

Oct 18 2022 | Jared Samuels - Manager

“President Biden’s “Executive Order on Lowering Prescription Drug Costs for Americans”

Insights,

Oct 06 2022 | Caitlin Sheetz, MPH - Head of SAVEs

ADVI SAVEs: UPDATE: Medicare Patients Receiving Aducanumab (Aduhelm™)

Insights,

Aug 12 2022 | Lindsay Bealor Greenleaf, JD, MBA - Head of Federal and State Policy

Congress just passed the Inflation Reduction Act, with prescription drug policies including government price setting, inflationary penalties, Part D benefit redesign, and a $35 insulin copay cap in Medicare.